This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

If You Care About Earnings, You Won't Want to Miss These

NEW YORK ( TheStreet) -- Investors have an vibrant earnings week starting Monday when over 400 companies report their latest quarterly results. You probably won't follow them all, and neither will I.

I selected the top most potentially market moving companies to concentrate on. My previous earnings preview focus was "Microsoft Is a Buy Before Earnings Release." Inside this preview, I will include specific companies that I may trade myself.

BMY Chart BMY data by YCharts

Bristol-Myers Squibb (BMY - Get Report)

Bristol-Myers Squibb, a biopharmaceutical company, engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products that help patients prevail over serious diseases worldwide.

52-Week Range: $30.64 to $41.79

Price To Book: 4.9

I wrote several bullish Bristol-Myers articles over the last year, and I remain optimistic. My latest article about this pharmaceutical targets the attractive dividend yield. "Three Dividend-Paying Value Stocks"

Bristol-Myers retraced slightly, but has yet to provide an entry in the upper $39s. We may receive an opportunity after reporting. Bristol-Myers Squibb is forecast to report weak first-quarter earnings before the market opens on Thursday.

The consensus estimate is currently 41 cents a share, falling 23 cents (35.9%) from 64 cents during the same period last year. The lowest analyst estimate for this report is 36 cents per share, and the highest is 45 cents per share.

video platformvideo managementvideo solutionsvideo player

Currently 13 out of 21 analysts rate the company a hold, while seven recommend buying and one recommends selling. Analysts may have missed a good one. In the last 12 months, the shares have substantially appreciated. The one year return is 22 percent, and the average analyst target price for Bristol-Myers Squibb is below the current market price at $37.28. The highest target is $45 with a low target of only $26.

The technical analysis appears strong. A rising 60-day moving average is above a rising 200 day moving average. Bristol-Myers is in a typical bull trend. Trend followers watch for this pattern and will hold a position until a technical break results in a signal to leave.

Bristol-Myers distributes $1.40 a year in dividends for an appealing yield of 3.4%. The combination of a large yield with strong fundamentals is why I featured it in the previously mentioned article. I believe they will beat the earnings estimate, but regardless, Bristol-Myers has the makings for a strong long-term hold.

At the time of writing and from the current short interest report, the short interest is slight and not a source of distraction. The small amount of short interest is 2.1%.

BMY Revenue Quarterly Chart BMY Revenue Quarterly data by YCharts
1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
BMY $70.78 -0.49%
CLF $4.24 -8.82%
DAL $41.43 -3.47%
FB $118.06 0.54%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs